Trinity Biotech has secured $7.0M in new funding, adding capital to the diagnostics company’s coffers as it continues to develop and market its line of test kits and equipment.
The company, which focuses on products used for clinical diagnosis, emphasizes the reliability and safety of its offerings, noting that results can shape life-changing decisions for patients. The fresh injection of funds arrives without specified investors or a disclosed round type, leaving the strategic purpose of the raise largely under wraps. Still, the capital bolsters a firm that operates across a broad range of diagnostic activities, from development to manufacturing, and employs a diverse team to support that work.
